Future 510(k) NSE Letters May Indicate If Alternative Classification Feasible
This article was originally published in The Gray Sheet
Executive Summary
FDA may indicate in future "not substantially equivalent" 510(k) letters whether or not the sponsor's device is a likely candidate for placement in Class I or Class II using the new alternative low-risk de novo device classification process established by Sec. 207 of the FDA Modernization Act.